Zhengkun Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhengkun Wang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Bomin Yan
Surgery, the Affiliated Hospital of Medical College, QingDao University, QingDao 266003, R. P. China
2 shared publications - Chunping Xia
Hepatobiliary surgery, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin 300060, China
2 shared publications - Kejun Zhang
The Affiliated Hospital of Qingdao University
2 shared publications - Lei Zhang
Molecular Biology, the Affiliated Hospital of Medical College, QingDao University, QingDao, Shan Dong Province 266003, P. R. China
2 shared publications - Qingfeng Chen
Surgery, the Affiliated Hospital of Medical College, QingDao University, QingDao 266003, R. P. China
2 shared publications - Shuhua Zhang
Surgery, the Affiliated Hospital of Medical College, QingDao University, QingDao 266003, R. P. China
2 shared publications
Latest Publications
- Open Access
- 3 July 2013
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 11 (1) , 149
Erratum to: Clusterin confers gemcitabine resistance in pancreatic cancer
- 3 July 2013
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 11 (1) , 149
Open AccessErratum to: Clusterin confers gemcitabine resistance in pancreatic cancer
- Open Access
- 24 May 2011
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 9 (1) , 59
Clusterin confers gmcitabine resistance in pancreatic cancer
Objective: To measure clusterin expression in pancreatic cancer tissues and cell lines and to evaluate whether clusterin confers resistance to gmcitabine in pancreatic cancer cells.Methods: Immunohistochemistry for clusterin was performed on 50 primary pancreatic cancer tissues and 25 matched backgrounds, and clusterin expression in 5 pancreatic cancer cell lines was quantified by Western blot and PT-PCR. The correlation between clusterin expression level and gmcitabine IC50 in pancreatic cancer cell lines was evaluated. The effect of an antisense oligonucleotide (ASO) against clusterin(OGX-011) on gmcitabine resistance was evaluated by MTT assays. Xenograft model was used to demonstrate tumor growth.Results: Pancreatic cancer tissues expressed significantly higher levels of clusterin than did normal pancreatic tissues (P< 0.01). Clusterin expression levels were correlated with gmcitabine resistance in pancreatic cancer cell lines, and OGX-011 significantly decreased BxPc-3 cells resistance to gmcitabine (P< 0.01).In vivosystemic administration of AS clusterin and gmcitabine significantly decreased the s.c. BxPC-3 tumor volume compared with mismatch control ODN plus gmcitabine.Conclusion: Our finding that clusterin expression was significantly higher in pancreatic cancer than in normal pancreatic tissues suggests that clusterin may confer gmcitabine resistance in pancreatic cancer cells.
- 24 May 2011
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 9 (1) , 59
Open AccessClusterin confers gmcitabine resistance in pancreatic cancer
Objective: To measure clusterin expression in pancreatic cancer tissues and cell lines and to evaluate whether clusterin confers resistance to gmcitabine in pancreatic cancer cells.Methods: Immunohistochemistry for clusterin was performed on 50 primary pancreatic cancer tissues and 25 matched backgrounds, and clusterin expression in 5 pancreatic cancer cell lines was quantified by Western blot and PT-PCR. The correlation between clusterin expression level and gmcitabine IC50 in pancreatic cancer cell lines was evaluated. The effect of an antisense oligonucleotide (ASO) against clusterin(OGX-011) on gmcitabine resistance was evaluated by MTT assays. Xenograft model was used to demonstrate tumor growth.Results: Pancreatic cancer tissues expressed significantly higher levels of clusterin than did normal pancreatic tissues (P< 0.01). Clusterin expression levels were correlated with gmcitabine resistance in pancreatic cancer cell lines, and OGX-011 significantly decreased BxPc-3 cells resistance to gmcitabine (P< 0.01).In vivosystemic administration of AS clusterin and gmcitabine significantly decreased the s.c. BxPC-3 tumor volume compared with mismatch control ODN plus gmcitabine.Conclusion: Our finding that clusterin expression was significantly higher in pancreatic cancer than in normal pancreatic tissues suggests that clusterin may confer gmcitabine resistance in pancreatic cancer cells.